Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy
Nicotine & Tobacco Research · 24.08.2026 · 28 (9) · 1596-1598
DOI: 10.1093/ntr/ntag039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nicotine & Tobacco Research, online erschienen am 26.03.2026. Verfasst von Mark L Rubinstein und 1 weiteren Autor:innen. Beteiligte Einrichtung: Achieve Life Sciences, Seattle, WA 98021, United States. Hauptthemen laut MEDLINE: Alkaloids, Quinolizines, Receptors, Serotonin, 5-HT3, Nausea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Achieve Life Sciences.
Abstract (Originalsprache)
Introduction
Cytisinicline is a novel smoking cessation medication that acts as a partial agonist at the α4β2 nicotinic acetylcholine receptor, similar to varenicline. However, cytisinicline is associated with a far lower incidence of nausea versus varenicline. Nausea with varenicline treatment may be due to its agonist activity at the 5-HT3 receptor, specifically the 5-HT3A subtype. This study investigated the receptor binding profile of cytisine (also known as cytisinicline) with respect to 5-HT3 binding.
Methods
Receptor binding assays evaluated cytisinicline binding at the α4β2 nicotinic and 5-HT3 receptors. Results are reported as the percentage displacement (inhibition) of radiolabeled ligand binding relative to a control appropriate for the receptor under test. The significance threshold was ≥50% displacement of radiolabeled ligand binding.
Results
Cytisinicline (10 μM) displaced 99% of the radiolabeled test ligand specific for the α4β2 nicotinic receptor, while at the same concentration, cytisinicline demonstrated no significant displacement of the radiolabeled test ligand for the 5-HT3 receptor (−8%), indicating a lack of measurable binding under the assay conditions. These results indicated the selectively targeted binding interaction of cytisinicline with α4β2 nicotinic receptors with minimal interaction with the 5-HT3 receptor.
Conclusions
Cytisinicline selectively targets the α4β2 nicotinic receptor with minimal interaction with the 5-HT3 receptor. Since activation of 5-HT3 receptors is known to induce nausea, this minimal binding interaction may help explain cytisinicline’s improved tolerability relative to varenicline, especially regarding the incidence of nausea. These findings support cytisinicline’s potential as a well-tolerated alternative for individuals who may not tolerate current smoking cessation therapies.
Implications
This study provides pharmacologic evidence that cytisinicline selectively interacts with the α4β2 nicotinic receptor while exhibiting minimal interaction with the 5-HT3 receptor, a key mechanism potentially underlying its improved gastrointestinal tolerability. These findings help explain the lower nausea rates observed in clinical trials and support cytisinicline as a promising alternative to varenicline for smoking cessation, particularly in individuals sensitive to medication-related side effects. This receptor-specific profile may enhance treatment adherence and expand the appeal of pharmacologic smoking cessation strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Achieve Life Sciences, Seattle, WA 98021, United States.
ORCID-Profile: Mark L Rubinstein, Cindy Jacobs
Förderung
- Achieve Life Sciences
Zitieren
APA
Rubinstein, M. L., & Jacobs, C. (2026). Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy. Nicotine & Tobacco Research, 28(9), 1596-1598. https://doi.org/10.1093/ntr/ntag039
Vancouver
Rubinstein ML, Jacobs C. Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy. Nicotine & Tobacco Research. 2026;28(9):1596-1598. doi:10.1093/ntr/ntag039
BibTeX
@article{Rubinstein2026,
author = {Rubinstein, Mark L and Jacobs, Cindy},
title = {Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy},
journal = {Nicotine & Tobacco Research},
year = {2026},
volume = {28},
number = {9},
pages = {1596--1598},
doi = {10.1093/ntr/ntag039}
}
EUVIMED